University of Salamanca   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Salamanca Spain (1255)

Organization Overview

First Clinical Trial
2003
NCT02701517
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aymara Abreu Corrales | Complejo Universitario de Salamanca | Fundación General de la Universidad de Salamanca | Guzmán Franch Arcas - C. A. U. Salamanca | Hospital Clinico de Salamanca | Hospital Clinico de Salamanca, Spain | Hospital Clinic of Salamanca | Hospital Clinico Universitario de Salamanca | Hospital Clínico Universitario de Salamanca | Hospital de Salamanca | Hospital Unisversitario de Salamanca | Hospital Universitario de Salamanca | Hospital Universitario de Salamanca (Salamanca) | Hospital Universitario de Salamanca, Salamanca. Spain. | Hospital Universitario Salamanca | IBSAL-Instituto de Investigación Biomédica de Salamanca | IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL | IBSAL - University Hospital of Salamanca | Instituto de Investigación Biomédica de Salamanca | Salamanca University | Universitario de Salamanca | University Clinical Hospital of Salamanca | University of Salamanca | University of Salamanca, Faculty of Medicine

Active Ingredients

Drugs in Phase 4 Trials (8)

dexamethasone (3 trials)

fluvastatin (lescol) (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

indocyanine green (ic-green) (1 trial)

iodine (1 trial)

levobupivacaine (chirocaine) (1 trial)

methylprednisolone (medrol) (2 trials)

ropivacaine (naropin) (1 trial)

Drugs in Phase 3 Trials (11)

allogeneic mesenchymal stem cells (1 trial)

amitriptyline (elavil) (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

cabazitaxel (jevtana kit) (1 trial)

citalopram (celexa) (1 trial)

etoricoxib (Gencox) (1 trial)

hyaluronic acid (1 trial)

lenalidomide (revlimid) (3 trials)

onabotulinumtoxinA (Botox) (1 trial)

quetiapine (seroquel) (1 trial)

raisin (1 trial)

Drugs in Phase 2 Trials (38)

abiraterone (zytiga) (1 trial)

alemtuzumab (campath) (1 trial)

allogeneic adipose derived mesenchymal stem cell (3 trials)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

autologous mesenchymal stem cells (1 trial)

axitinib (inlyta) (1 trial)

azacitidine (vidaza) (1 trial)

belantamab mafodotin (TECVAYLI) (2 trials)

bendamustine (treanda) (3 trials)

beta erythropoietin (1 trial)

bortezomib (velcade) (3 trials)

brentuximab vedotin (adcetris) (1 trial)

carfilzomib (kyprolis) (1 trial)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

ibrutinib (imbruvica) (1 trial)

melphalan (alkeran) (1 trial)

mitomycin (mutamycin) (1 trial)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (1 trial)

octreotide (sandostatin) (1 trial)

ofatumumab (arzerra) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (2 trials)

panitumumab (vectibix) (2 trials)

platelet-rich plasma (1 trial)

ponatinib (iclusig) (1 trial)

prednisone (meticorten) (3 trials)

rituximab (rituxan) (5 trials)

urea (3 trials)

vincristine (oncovin) (1 trial)

Drugs in Other Trials (5)

clopidogrel (plavix) (1 trial)

multivitamins (1 trial)

prasugrel (effient) (1 trial)

propofol (diprivan) (1 trial)

ticagrelor (brilinta) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Aggression (Phase 2)

Anemia (Phase 2)

Anus Neoplasms (Phase 2)

Aortic Valve Stenosis (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Constriction, Pathologic (Phase 4)

Delirium (Phase 3)

Graft vs Host Disease (Phase 2)

Graves Disease (Phase 4)

Head and Neck Neoplasms (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis, Viral, Human (Phase 4)

Hodgkin Disease (Phase 2)

Hyperthyroidism (Phase 4)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukopenia (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neuroendocrine Tumors (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Preleukemia (Phase 3)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Syndrome (Phase 3)

Thrombocytopenia (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial APIs: 62